Recent News
Alarm Bells are Ringing: Medicare Drug Price Negotiation Program Will Fail Without Changes
March 4, 2025 | By B. Douglas Hoey, RPh, MBA If CMS doesn’t reconsider its mandate, which forces independent pharmacies to go deep into a hole and lose money, many of them will close. On either side of the political aisle, you’ll find a desire to reduce prescription drug cost for Americans. Former President Biden made the Medicare Drug Price...
Congress Should Pass the EPIC Act to Fix Incentives for Small-Molecule Drugs; New Report Shows IRA Undermines Pharmaceutical Innovation
WASHINGTON—The Biden-era Inflation Reduction Act (IRA) undermines incentives to produce new innovations in small-molecule drugs and therefore could slow advances to treat diseases and conditions ranging from high blood pressure to Parkinson’s, according to a new report from the Information Technology and Innovation Foundation (ITIF),...
CMS Doubles Down on Medicare Drug Price Controls,Threatening Patient Access and Innovation
Published 11:47 AM EST, January 22, 2025ARLINGTON, VIRGINIA / ACCESS Newswire / January 22, 2025 The Centers for Medicare & Medicaid Services (CMS) has announced an additional 15 drugs that will be subject to price controls under the Inflation Reduction Act(IRA). This expansion continues a flawed policy that threatens innovation and...
Congress Should Pass the EPIC Act to Fix Incentives for Small-Molecule Drugs; New Report Shows IRA Undermines Pharmaceutical Innovation
WASHINGTON—The Biden-era Inflation Reduction Act (IRA) undermines incentives to produce new innovations in small-molecule drugs and therefore could slow advances to treat diseases and conditions ranging from high blood pressure to Parkinson’s, according to a new report from the Information Technology and Innovation Foundation (ITIF),...
CMS Doubles Down on Medicare Drug Price Controls,Threatening Patient Access and Innovation
Published 11:47 AM EST, January 22, 2025ARLINGTON, VIRGINIA / ACCESS Newswire / January 22, 2025 The Centers for Medicare & Medicaid Services (CMS) has announced an additional 15 drugs that will be subject to price controls under the Inflation Reduction Act(IRA). This expansion continues a flawed policy that threatens innovation and...
ASBM Comments on CMS Medicare – Price Negotiation Guidance
April 14, 2023 Re: Medicare Drug Price Negotiation Program GuidanceSubmitted via email to: IRARebateandNegotiation@cms.hhs.gov Dear Sir or Madam, Thank you for the opportunity to provide comments on the initial guidance memorandum regarding implementation of the Medicare Drug Price Negotiation Program. The Alliance for Safe Biologic Medicines...
CMS Doubles Down on Medicare Drug Price Controls, Threatening Patient Access and Innovation
The Centers for Medicare & Medicaid Services (CMS) has announced an additional 15 drugs that will be subject to price controls under the Inflation Reduction Act (IRA). This expansion continues a flawed policy that threatens innovation and jeopardizes patient access to critical treatments, including drugs vital for cancer treatment and popular new weight loss medications that have transformed the management of obesity and related conditions.
ASBM Comments to CMS Opposing IRA’s Medicare Part D Redesign
“It is ASBM’s position that patients should have access to innovative medicines, and that biosimilars are an important tool to expand access by creating cost savings through market competition.”